JP2017512838A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512838A5
JP2017512838A5 JP2017502946A JP2017502946A JP2017512838A5 JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5 JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
antibody
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502946A
Other languages
English (en)
Japanese (ja)
Other versions
JP6598844B2 (ja
JP2017512838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023108 external-priority patent/WO2015148984A2/en
Publication of JP2017512838A publication Critical patent/JP2017512838A/ja
Publication of JP2017512838A5 publication Critical patent/JP2017512838A5/ja
Application granted granted Critical
Publication of JP6598844B2 publication Critical patent/JP6598844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502946A 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 Active JP6598844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014074199 2014-03-27
CNPCT/CN2014/074199 2014-03-27
CN2014081797 2014-07-08
CNPCT/CN2014/081797 2014-07-08
PCT/US2015/023108 WO2015148984A2 (en) 2014-03-27 2015-03-27 Antibodies that bind human cannabinoid 1 (cb1) receptor

Publications (3)

Publication Number Publication Date
JP2017512838A JP2017512838A (ja) 2017-05-25
JP2017512838A5 true JP2017512838A5 (enExample) 2018-05-17
JP6598844B2 JP6598844B2 (ja) 2019-10-30

Family

ID=53008849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502946A Active JP6598844B2 (ja) 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体

Country Status (16)

Country Link
US (4) US10308712B2 (enExample)
EP (2) EP3122780B1 (enExample)
JP (1) JP6598844B2 (enExample)
KR (2) KR102553870B1 (enExample)
CN (1) CN106232626B (enExample)
AU (1) AU2015237275B2 (enExample)
CA (1) CA2944049A1 (enExample)
CL (3) CL2016002433A1 (enExample)
ES (1) ES2915101T3 (enExample)
IL (1) IL248006B2 (enExample)
MA (1) MA39708A (enExample)
MX (1) MX2016012403A (enExample)
PE (1) PE20170258A1 (enExample)
RU (1) RU2730674C2 (enExample)
TW (1) TWI694086B (enExample)
WO (1) WO2015148984A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
IL300015A (en) * 2015-09-30 2023-03-01 Bird Rock Bio Inc Antibodies that bind human cannabinoid receptor 1
AU2018282094B2 (en) * 2017-06-05 2024-06-27 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
CN110914430B (zh) * 2017-07-13 2023-11-21 协和麒麟株式会社 抗bril抗体以及使用了该抗体的bril融合蛋白质的稳定化方法
CN108588071A (zh) * 2018-04-25 2018-09-28 和元生物技术（上海）股份有限公司 CRISPR-Cas9靶向敲除人肠癌细胞CNR1基因及其特异性的sgRNA
SG11202010388SA (en) 2018-04-30 2020-11-27 Takeda Pharmaceuticals Co Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
US20210267959A1 (en) * 2018-07-17 2021-09-02 The Regents Of The University Of California Methods of treating renal disease
WO2021007533A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
EP4504792A2 (en) * 2022-04-04 2025-02-12 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
US20250326836A1 (en) 2022-06-03 2025-10-23 Shionogi & Co., Ltd. Antibody that binds to cannabinoid type 1 receptors
CN119585311A (zh) * 2022-07-28 2025-03-07 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2024212999A1 (zh) * 2023-04-11 2024-10-17 微境生物医药科技(上海)有限公司 Cbl-b抑制剂
CN118027211A (zh) * 2024-04-11 2024-05-14 上海惠盾因泰生物科技有限公司 一种识别重组egf-crm197疫苗的单克隆抗体及其应用
CN120647762A (zh) * 2025-06-16 2025-09-16 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
EP1641493A4 (en) 2003-06-30 2007-10-31 Merck & Co Inc RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS
US20050095674A1 (en) 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
UA99620C2 (en) 2007-05-23 2012-09-10 Мерк Шарп Энд Доме Корп. Pyridyl piperidine orexin receptor antagonists
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) * 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
EA029400B1 (ru) * 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
HRP20170502T1 (hr) 2011-05-20 2017-06-16 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagonisti cb 1 receptora
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2698383B1 (en) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Detection of synthetic Cannabinoids
JP6562912B2 (ja) 2013-06-26 2019-08-21 アムジェン インコーポレイテッド Ｃｂ１受容体抗原結合タンパク質及びその使用
AU2014361856A1 (en) 2013-12-12 2016-06-30 Abbvie Stemcentrx Llc Novel anti-DPEP3 antibodies and methods of use
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체

Similar Documents

Publication Publication Date Title
JP2017512838A5 (enExample)
RU2016141919A (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
JP6681433B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
AU2018312222B2 (en) Anti-CD47 antibodies and uses thereof
JP7273110B2 (ja) 高親和性抗ｖｅｇｆ抗体
JP2018503380A5 (enExample)
JP2020501531A5 (enExample)
JP2017526370A5 (enExample)
JP2012501669A5 (enExample)
TW202144417A (zh) Ｐｖｒｉｇ結合蛋白及其醫藥用途
JP2008516970A5 (enExample)
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2012501670A5 (enExample)
JP2014500009A5 (enExample)
JP2013502913A5 (enExample)
JP2015530971A5 (enExample)
JP2010526028A5 (enExample)
JP2011207882A5 (enExample)
JP2015533853A5 (enExample)
JP2013538057A5 (enExample)
JP2011520898A5 (enExample)
JP2022507679A (ja) Ｈｅｒ２／ｐｄ１二重特異性抗体
JP2014524733A5 (enExample)
TWI869528B (zh) C5ar1抗體分子及其用途
WO2011094465A4 (en) Methods of treating autoimmune diseases with dll4 antagonists